Effects of statin therapy on coronary plaque volume by decreasing CRP/hsCRP levels: A meta-regression of randomized controlled trials

Darui Gao, Rong Hua, Dina Jiesisibieke, Yanjun Ma, Chenglong Li, Sijing Wu, Qian Ma, Wuxiang XiemedRxiv 2021 · DOI

TL;DR

This meta-analysis of 12 randomized controlled trials reveals that statins promote the regression of coronary plaque primarily through their anti-inflammatory effects, measured by reductions in C-reactive protein (CRP/hsCRP). Surprisingly, the study found that the degree of plaque shrinkage was significantly associated with the drop in inflammation levels, even when accounting for the reduction in "bad" cholesterol (LDL-C).

What Problem Does This Paper Address?

Coronary Heart Disease (CHD) remains a leading cause of death globally, driven by atherosclerosis—the buildup of fatty plaques in artery walls. While statins are the gold standard for treatment, scientific debate has persisted regarding how they actually stabilize and reverse these plaques.

Is it purely because they lower Low-Density Lipoprotein Cholesterol (LDL-C), or is it due to their "pleiotropic" effects—additional benefits like reducing vascular inflammation? Previous studies have offered inconsistent findings. This paper aims to settle the score by using meta-regression to isolate the impact of inflammation reduction (measured via CRP/hsCRP) on coronary plaque volume.

Methods

The researchers conducted a systematic review of randomized controlled trials (RCTs) up to May 2021. They specifically looked for studies that used Intravascular Ultrasound (IVUS)—a high-resolution imaging technique that allows for precise volumetric measurement of plaques—rather than traditional angiography.

Key methodological steps included:

  • Selection Criteria: Only RCTs with at least six months of follow-up that reported both baseline and end-of-study values for LDL-C and CRP/hsCRP were included.
  • Metrics: They analyzed Total Atheroma Volume (TAV), Plaque Volume (PV), and Percent Atheroma Volume (PAV).
  • Statistical Analysis: The team used a random-effects model to calculate Standardized Mean Differences (SMD). Crucially, they employed meta-regression to see if the percentage change in CRP or LDL-C could predict the amount of plaque regression, while adjusting for age and gender.

Datasets

The study synthesized data from 12 RCTs involving a total of 2,812 subjects.

  • The trials spanned several countries (China, USA, Korea, Japan) and were published between 2004 and 2016.
  • The analysis covered 16 treatment arms using various statins: Atorvastatin (10-80 mg/day), Rosuvastatin (10-40 mg/day), Pravastatin (20 mg/day), and Pitavastatin (4 mg/day).

Key Insights and Ideas

  • The "Anti-Inflammatory" Driver: The most significant "aha" moment is that the reduction in CRP/hsCRP was a statistically significant predictor of plaque regression. In the meta-regression models, the more a patient's inflammation dropped, the more their plaque volume decreased.
  • LDL-C vs. CRP: While LDL-C reduction is vital for preventing heart attacks, this specific analysis found that LDL-C changes did not statistically influence the reduction in plaque volume (TAV/PV) once other factors were considered. This suggests that for the specific goal of shrinking existing plaque, the anti-inflammatory effect of statins might be the dominant mechanism.
  • Pleiotropic Independence: The findings imply that statins promote plaque regression independently of their ability to regulate LDL-C. This reinforces the idea of CRP as a critical therapeutic target in its own right.

Key Results

  • Overall Plaque Reduction: Statin therapy led to a significant reduction in plaque volume compared to control groups.
  • TAV/PV: SMD of -0.27 (95% CI: -0.42 to -0.12).
  • PAV: SMD of -0.16 (95% CI: -0.29 to -0.03).
  • Meta-Regression Findings:
    • The percent change in CRP/hsCRP was significantly associated with the change in TAV/PV ($p < 0.05$), even after adjusting for LDL-C, age, and gender.
  • The regression coefficient ($\beta$) for CRP on TAV/PV was 0.0064 in the primary model, increasing to 0.0119 when adjusted for LDL-C.

Limitations and Future Work

The authors acknowledge several hurdles:

  • Database Scope: The search was limited to three major databases (PubMed, EMBASE, Cochrane), potentially missing gray literature or studies in other languages.
  • Blinding: Not all included RCTs were double-blind, which introduces a risk of performance bias.
  • Statistical Power for PAV: The meta-regression for Percent Atheroma Volume (PAV) only included seven trials, which may have lacked the statistical power to show the same clear association found with Total Atheroma Volume.
  • Future Directions: The researchers suggest that future studies should focus more intensely on anti-inflammatory therapies that don't affect lipid levels to further validate CRP as a primary therapeutic target for plaque regression.

Summary updated

Abstract

Abstract Background and aims Several clinical trials have indicated that statins stabilize and reverse atherosclerotic plaque. However, different studies have provided inconsistent findings regarding mechanisms and influencing factors of plaque regression under statin therapy. In this study, meta-analysis and meta-regression were used to determine the effects of statin medications on coronary plaque volume as determined by intravenous ultrasound. Meanwhile, the impact of CRP/hsCRP reduction during statin therapy on plaque regression was investigated. Methods Up to May 28, 2021, a systematic PubMed, EMBASE, and Cochrane search was performed for randomized controlled trials that assessed treatment effect using total atheroma volume (TAV), percent atheroma volume (PAV), or plaque volume (PV). Only CRP/hsCRP and LDL-C values reported before and after treatment were considered. Results 12 studies fulfilled the inclusion criteria and were included in the systematic review. A meta-analysis of 15 statin-treated arms reported a significant reduction in change of TAV/PV (standardized mean difference [SMD]: −0.27, 95% confidence intervals [CI]: −0.42, −0.12), compared with the control arms. Another meta-analysis of 7 trials also found that patients in the intervention group had a significant reduction in change of PAV (SMD: −0.16, 95% CI: −0.29, −0.03), compared with those in the control group. Meta-regression analysis revealed the percent change of CRP/hsCRP statistically influences SMD in change of TAV/PV after adjusting for percent change of LDL-C, age and gender. Meta-regression analysis showed that percent change of CRP/hsCRP statistically influences SMD in change of PAV. Conclusion In conclusion, statin therapy is beneficial for plaque regression. Statins promote plaque regression through their anti-inflammatory ability.
BibTeX
@misc{gao2021effects,
  author = {Darui Gao and Rong Hua and Dina Jiesisibieke and Yanjun Ma and Chenglong Li and Sijing Wu and Qian Ma and Wuxiang Xie},
  title = {{Effects of statin therapy on coronary plaque volume by decreasing CRP/hsCRP levels: A meta-regression of randomized controlled trials}},
  year = {2021},
  doi = {10.1101/2021.12.26.21268412},
  howpublished = {medRxiv},
}
Figure